ホームページへ
4.6/5
TrustPilot

トルコで最高のCAR-T細胞療法医師 - トップ12名の医師

トルコのトップCAR-T細胞療法医師と価格を比較。こちらで最適なマッチングを見つけてください

トルコの3名のトップCAR-T細胞療法専門家から見積もりを取得

ご要望と予算に基づいて最適な医師を厳選いたします

トップ医師

12

トルコ

レビュー

14000+

実際の患者より

医師サービスで最良価格の国を選択

トップ各国のCAR-T細胞療法価格を比較

国をタップしてトップ医師と価格を表示

Israel
Ukraine
Turkey
Poland
Mexico
Thailand
$72,000 - $112,800
$150,000 - $250,000
$150,000 - $225,000
$150,000 - $250,000
$250,000 - $400,000
$250,000 - $350,000
$0
$64,000
$128,000
$192,000
$256,000
$320,000
$384,000

個別化された治療計画を無料で取得し、最良のオプションを選択してください。コミットメント不要 · サービス料金なし

最初に表示:

Bulent Eser

  • 新着
  • 36年の経験
  • 所在地: トルコ, アンタルヤ
  • Experience

    • 1990 - 1994 – General Practitioner
    • 1994 - 2001 – Research Assistant, Erciyes University, Faculty of Medicine
    • 2001 - 2006 – Assistant Professor, Internal Medicine/Hematology, Erciyes University, Faculty of Medicine
    • 2006 - 2011 – Associate Professor, Internal Medicine/Hematology, Erciyes University, Faculty of Medicine
    • 2011 - 2019 – Professor, Internal Medicine/Hematology, Erciyes University, Faculty of Medicine

    Professional Memberships

    • Turkish Society of Hematology
    • European Group for Blood and Marrow Transplantation (EBMT)
    • Hematologic Oncology Association
    • Antalya Medical Chamber
  • 続きを読む
診察
お問い合わせください

Ceyhun Bozkurt

  • 新着
  • 36年の経験
  • 所在地: トルコ, イスタンブール
  • Prof. Dr. Ceyhun Bozkurt is a respected Pediatric Hematologist-Oncologist. He is known for his work in childhood blood disorders and cancers. He graduated from Cerrahpaşa Faculty of Medicine. He holds specializations in both Pediatrics and Pediatric Oncology. Since 2019, he has been Professor and Clinical Director at Bahçelievler Medical Park Hospital. He also serves as Vice Director of the Stem Cell Transplant Unit.

    Dr. Bozkurt has published over 40 peer-reviewed articles. He is recognized for his work in leukemia, bone marrow transplantation, and stem cell therapy. He is a member of organizations such as SIOP and EBMT. His memberships show his dedication to high standards in clinical care and research.

  • 続きを読む
診察
お問い合わせください

Mustafa Serkan Alemdar

  • 新着
  • 20年の経験
  • 所在地: トルコ, アンタルヤ
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • 続きを読む
診察
お問い合わせください

Serdar Bedii Omay

  • 4 良い 1 レビュー
  • 36年の経験
  • 所在地: トルコ, イスタンブール
  • クリニック:
    4.4
    Emsey Hospital
  • Serdar Bedii Omay教授は、血液学および骨髄移植の分野において65本以上の科学論文を発表しています。三重大学医学部にて分子血液学の研鑽を積みました。

    • 数十年にわたる豊富な経験を持つ血液学教授
    • 65本以上の論文および112本の学会発表論文を執筆
    • 三重大学医学部にて分子血液学を専門的に修得
  • 続きを読む
診察
お問い合わせください

Adem Topaloglu

  • 新着
  • 15年の経験
  • 所在地: トルコ, イスタンブール
  • クリニック:ERDEM HOSPITAL
  • Dr. Adem Topaloglu is a general surgeon with expertise in laparoscopic oncology. He focuses on colon and rectal cancers. He graduated from Karadeniz Technical University Faculty of Medicine in 1998. He completed his general surgery training at Eskişehir Osmangazi University in 2009.

    Dr. Topaloglu performs advanced minimally invasive surgeries. His procedures include laparoscopic gastric, colon, and rectal cancer surgeries, as well as anti-reflux surgery, hernia repairs, appendectomy, and cholecystectomy. He is also experienced in endocrine and gastroenterological surgeries. In addition, he performs bariatric procedures such as gastric sleeve, bypass, and balloon interventions.

    Dr. Topaloglu holds certifications in obesity, hiatal, and inguinal hernia surgeries. He is skilled in gastroscopy and colonoscopy. His expertise helps improve patient outcomes and surgical success rates.

  • 続きを読む
診察
お問い合わせください

Rafet Eren

  • 新着
  • 19年の経験
  • 所在地: トルコ, イスタンブール
  • クリニック:Biruni University Hospital
  • Education

    • Undergraduate: Istanbul Faculty of Medicine, Istanbul University, 2007
    • MSc (Internal Medicine Department): Marmara University Faculty of Medicine, 2012
    • PhD (Hematology Clinic): Istanbul Training and Research Hospital, 2018
    • Associate Professor (Hematology Clinic): Prof.Dr.Cemil Tascioglu Training and Research Hospital, 2019

    Prof. Dr. Rafet Eren graduated from Istanbul Faculty of Medicine in 2007. He completed his Internal Medicine specialty training at Marmara University Faculty of Medicine in 2012. In 2018, he became a Hematology subspecialist at Istanbul Training and Research Hospital. In 2019, he was awarded the title of Associate Professor in the field of Hematology. Afterwards, he worked as a faculty member at Başakşehir Çam and Sakura City Hospital, Bozyaka Training and Research Hospital and Istinye University (Istinye University Bahçeşehir and Liv Hospital Vadistanbul) and is currently working at Biruni University Hospital. Dr. Rafet Eren is a member of Turkish Society of Hematology, Hematology Specialty Society and European Society of Hematology and speaks English fluently. He has around 50 publications in national and international refereed journals.

    Scientific Memberships

    • Turkish Hematology Association
    • Hematology Specialty Society
    • Turkish Internal Medicine Specialty Society
    • European Society of Hematology
    •  

    Awards 

    • Young Researcher Award (42nd National Hematology Congress), 2016
    • Special Jury Paper Award (3rd Hematologic Oncology Congress), 2015
    • Paper 3rd Prize (2nd Hematologic Oncology and Bone Marrow Transplantation Symposium), 2016
  • 続きを読む
診察
お問い合わせください

Hilmi Apak

  • 新着
  • 26年の経験
  • 所在地: トルコ, イスタンブール
  • クリニック:Biruni University Hospital
  • Dr. Hilmi Apak is a respected pediatric hematology-oncology specialist with more than 21 years of experience. He is trained in pediatric oncology. Dr. Apak has led advanced treatments, including bone marrow transplantation, leukemia chemotherapy, and CAR T-cell therapy.

    He has published 75 international medical articles, showing his strong contribution to pediatric oncology research. Dr. Apak has worked as assistant editor for the Turkish Pediatrics Archives Periodical. He has also held important academic and leadership positions, such as Head of Pediatric Hematology-Oncology at Istanbul University-Cerrahpaşa.

  • 続きを読む
診察
お問い合わせください

Birol Baytan

  • 新着
  • 34年の経験
  • 所在地: トルコ, イスタンブール
  • クリニック:
    4.4
    Emsey Hospital
  • 経歴と教育

    ベイタン教授は1992年にアンカラ大学医学部を卒業し、ウルドゥグ大学医学部児童疾患学科で医学の専門家となりました。2002年には、同じ機関で小児血液学の助教授として働きました。

    彼はまた、小児がん、白血病(リンパ腫)、小児出血性疾患の治療、血管閉塞、貧血治療、鉄欠乏症およびビタミン欠乏症の治療などの診断と治療に特化しています。

     

    学術経験

    ベイタン教授は、国際査読付きジャーナルに発表された15の論文、国際科学会議で発表および出版された9つの全文、地方/外国語で書かれた3つの書籍/書籍の章、地方査読付きジャーナルに公開された8つの論文を有しています。

     

     

  • 続きを読む
診察
お問い合わせください

Osman Ilhan

  • 新着
  • 48年の経験
  • 認定:
  • 所在地: トルコ, アンカラ
  • Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.

    His medical interests include:

    Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)

    Acute Leukemia

    Chronic Leukemia Treatments

    Hodgkin Lymphoma

    Non-Hodgkin Lymphoma Treatments

    Multiple Myeloma Treatments, MDS

    Aplastic Anemia

    ITP

    TTP Treatments

    Hypercoagulability

    Hereditary Thrombophilia Treatments

    Therapeutic Apheresis

    Photopheresis

    Geriatric Hematology Diseases.

  • 続きを読む
診察
お問い合わせください

Itir Sirinoglu Temiz

  • 新着
  • 36年の経験
  • 所在地: トルコ, イスタンブール
  • クリニック:
    5.0
    Liv Hospital Vadistanbul
  • Dr. Itir Sirinoglu Temiz is a Professor of Hematology. She specializes in lymphoma, acute and chronic leukemias, multiple myeloma, thrombocytopenias, thrombosis, anemia, and bone marrow failure. She graduated with honors from Istanbul University Cerrahpaşa Faculty of Medicine. She completed her hematology training at Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital.

    Dr. Sirinoglu Temiz has held key academic and administrative positions. She served as Head of Internal Medicine at IAU Faculty of Medicine. She was also Education and Administrative Manager at SBÜ Bakırköy Dr. Sadi Konuk EAH Hematology Clinic. She has broad experience in adult hematology, stem cell transplantation, and therapeutic apheresis. She currently practices at Liv Hospital.

  • 続きを読む
診察
お問い合わせください

Ali Hakan Kaya

  • 新着
  • 20年の経験
  • 所在地: トルコ, イスタンブール
  • クリニック:Biruni University Hospital
  • Education

    • Faculty of Medicine - Cerrahpaşa Faculty of Medicine 1999-2005
    • Internal Medicine Residency - Istanbul Haseki Training and Research Hospital 2006-2010
    • Hematology Subspecialist Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital - Hematology and Stem Cell Transplant Clinic 2013-2017
    • Associate ProfessorIstanbul Ümraniye Training and Research Hospital 2019
    •  

    Experience

    • Assistant Doctor Istanbul Haseki Training and Research Hospital - Internal Medicine Clinic 2006-2010
    • Internal Medicine Specialist Istanbul Esenyurt State Hospital 2010-2012
    • Internal Medicine Specialist-Military service Samsun Military Hospital 2012-2013
    • Subspecialty Training Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital - Hematology and Stem Cell Transplant Clinic 2013-2017
    • Hematology Subspecialist Ankara Gülhane Training and Research Hospital, Hematology and Stem Cell Transplant Clinic 2017-2018
    • Hematology Subspecialist Istanbul Ümraniye Training and Research Hospital/Hematology 2018-2019
    • Associate Professor Istanbul Ümraniye Training and Research Hospital/Hematology 2019-2021
    • Associate Professor Maltepe University Faculty of Medicine / Hematology 2021-2024
    • Associate Professor Istanbul VM Medical Park Pendik Hospital / Hematology and Stem Cell Transplant Clinic 2022-2024
    •  

    Scientific Memberships

    • Turkish Medical Association
    • Turkish Apheresis Society
    • Hematologic Oncology Society
    • Blood and Bone Marrow Transplant Association
    • Hematologic Immunology Society
    •  

    Awards

    •  
    • Hematologic Oncology Society, 2015 - Second Prize for Paper
    • Hematologic Oncology Society, 2016 - Second Prize for Paper
    • Turkish Apheresis Association, 2016 - Paper Third Prize,
    • Hematologic Immunology Association, 2016 - Second Prize for Paper
    • Hematologic Oncology Society, 2016 - Second Prize for Paper
    • Blood and Bone Marrow Transplantation Association, 2017 - First Prize for Paper
       
  • 続きを読む
診察
お問い合わせください

海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。

ヤン・マツィイフスキー

医療コーディネーターチーム責任者

4300+件以上の患者の旅をガイド

Bookimedで3

Turkeyの278名の患者が今月当社を通じて医師を見つけました

完璧な医師マッチングを取得する方法

1

2分のクイズ

目標、予算、スケジュールをお聞かせください

2

人間のマッチング + AI

アルゴリズムがマッチングを見つけ、コーディネーターが適合性を確認します

3

オプション準備完了

価格、パッケージ、日程を比較。コーディネーターとチャット

選択肢に迷っていますか?

専属の Bookimedコーディネーターがお客様のニーズに合わせた完璧な外科医を見つけるお手伝いをします

  • すべての段階で24時間365日サポート
  • 医師とのマッチングサポートとクリニックとの全てのコミュニケーションを処理
  • 旅行、宿泊、送迎を調整します

治療をガイド

医療訓練を受けた専属コーディネーター

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk

適切な医師とクリニックの選び方:内部者のヒント

医師やクリニックを選ぶ際は、これらの重要なポイントを覚えておいてください:
資格を確認
ISAPS、JCI、または関連医学会などの機関からの認証を確認してください
成功率を確認
お客様の特定治療に豊富な経験と実績のある医師をお選びください
患者レビューを読む
実際の患者様のBookimedレビューをご覧になり、体験について学んでください
効果的なコミュニケーションの確保
円滑な治療のため言語サポートを提供するクリニックを選んでください。
サービスについて質問
隠れた費用を避けるため、価格に宿泊、現地送迎、アフターケアなどのサービスが含まれているかご確認ください

Bookimed洞察:トルコのトップCAR-T細胞療法専門家(2026)

BookimedはトルコのCAR-T細胞療法リクエスト29件を調整し、12名のトップ評価専門家と協力しています。この表の医師は国際的資格、臨床専門知識、患者の結果に基づいて選ばれています。2026年ランキングは実際の患者ケースとパートナークリニックの現行プログラムからの検証済みデータを使用して形成されています
順位医師経験適合する方特色クリニックと所在地診察
#136年の経験CAR T細胞療法分子血液学を専門とし、最先端治療の研究に従事。血液学および骨髄移植に関する論文を65本以上発表。エーゲ大学およびカラデニズ工科大学の教授。
トルコ
から $110

FAQ

これらのFAQはBookimedを通じて医療支援を求める実際の患者からのものです。回答は経験豊富な医療コーディネーターと信頼できるクリニック代表者が行います。

How are side effects like CRS or neurotoxicity managed?

CAR T-cell therapy side effects are managed through a tiered protocol of anti-cytokine medications and corticosteroids. In Turkey, Joint Commission International-accredited centers utilize tocilizumab to reverse cytokine release syndrome and dexamethasone for neurotoxicity. Clinical teams provide 24-hour monitoring during a 28-day inpatient stay to ensure immediate intervention.

  • Cytokine Release Syndrome: Managed with intravenous tocilizumab (IL-6 inhibitor) to block systemic inflammatory responses.
  • Neurotoxicity (ICANS): Treated primarily with high-dose dexamethasone as tocilizumab cannot cross the blood-brain barrier.
  • Seizure prophylaxis: Neurologists prescribe levetiracetam and perform daily cognitive assessments using the standardized ICE score.
  • Supportive care: Includes aggressive hydration, antipyretics for fever, and supplemental oxygen within intensive care units.

Bookimed Expert Insight: While many believe CAR-T requires only a short visit, Turkey’s top hematologists at clinics like Istanbul Florence Nightingale enforce a strict 28-day hospitalization. This duration is not just for observation; it ensures immediate access to tocilizumab, which must be administered within hours of a fever to prevent higher-grade complications. With packages around $200,000—compared to $525,000 in the US—this extended stay is a critical safety buffer that is often financially inaccessible elsewhere.

Patient Consensus: Patients report that low-grade side effects feel like a severe flu. They emphasize that early reporting of tremors or confusion is vital, as symptoms typically resolve within 1–3 days after receiving the correct medication.

Which hospitals in Turkey are known for CAR T-cell therapy?

Leading Turkish hospitals for CAR T-cell therapy include Anadolu Medical Center, Memorial Şişli, and Medical Park Bahçelievler. These JCI-accredited facilities treat complex blood cancers using advanced cellular immunotherapy. Specialized centers in Istanbul and Ankara provide required 28-day monitoring periods overseen by hematologists from the European Bone Marrow Transplant Group.

  • Anadolu Medical Center: Affiliated with Johns Hopkins Medicine, maintaining JACIE-accredited bone marrow transplant standards.
  • Istanbul Florence Nightingale: Features a Mayo Clinic-trained hematologist and Turkey's first certified smart-and-green hospital facility.
  • Medical Park Bahçelievler: Offers specialized pediatric CAR T-cell programs led by SIOP and EBMT-certified experts.
  • Memorial Şişli Hospital: The first JCI-accredited hospital in Turkey, known for high-volume cellular therapy procedures.

Bookimed Expert Insight: While many global centers offer CAR T-cell therapy, Turkish clinics like Medical Park Bahçelievler and Istanbul Florence Nightingale distinguish themselves by including 28 full days of inpatient hospitalization. This extensive stay is crucial for managing potential side effects like cytokine release syndrome and is often bundled into the procedure price, whereas US facilities frequently charge these as separate, significant daily costs.

Patient Consensus: Patients emphasize the importance of verifying whether the protocol is a local clinical trial or an internationally approved treatment. Many choose private centers like Acibadem or Anadolu to bypass the bureaucratic delays often found in public university research hospitals.

Is CAR T-cell therapy available in Turkey?

CAR T-cell therapy is available in Turkey at specialized JCI-accredited hematology centers for treating relapsed B-cell malignancies. Leading facilities like Istanbul Florence Nightingale Hospital and Memorial Healthcare Group provide these advanced immunotherapies, often at 64% lower costs than the United States.

  • Treatment focus: Primarily targets acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).
  • Hospital stay: Most protocols require a 28-day stay for intensive side-effect monitoring.
  • Cell manufacturing: Engineering the patient's T-cells typically requires a 2-to-3 month wait.
  • Expert access: Surgeons like Dr. Osman Ilhan performed Turkey's first stem cell transplants.

Bookimed Expert Insight: While base procedure prices range from $150,000 to $225,000, the diagnostic phase is exceptionally thorough in Turkey. Clinics like Medical Park Bahcelievler include specialized cardiac mapping and PET/CT scans in their CAR-T packages. This comprehensive screening is vital because the therapy places significant stress on the cardiovascular system.

Patient Consensus: Patients emphasize the importance of verifying if the clinic uses EMA-approved products. They often recommend budgeting for an extended stay beyond the initial 4-week hospitalization.

Which hospitals in Turkey are known for CAR T-cell therapy?

Leading Turkish hospitals for CAR T-cell therapy include Istanbul Florence Nightingale, Anadolu Medical Center, and Biruni University Hospital. These JCI-accredited facilities feature specialized bone marrow transplant units and multidisciplinary teams of hematologists and oncologists. They manage complex cell collection, genetic engineering, and intensive post-infusion monitoring for refractory blood cancers.

  • Specialized infrastructure: Anadolu Medical Center maintains a dedicated 45-bed bone marrow unit for side-effect monitoring.
  • Expert hematologists: Dr. Omur Gokmen Sevindik at Florence Nightingale trained at the renowned Mayo Clinic.
  • Pediatric excellence: Medical Park Bahcelievler offers SIOP-certified programs led by Clinical Director Dr. Ceyhun Bozkurt.
  • Academic research: Biruni University Hospital integrates advanced genetic sequencing and mutation analysis into treatment protocols.

Bookimed Expert Insight: While many clinics claim oncology expertise, the true differentiators for CAR T-cell therapy in Turkey are the in-house manufacturing capabilities and physician research backgrounds. For instance, Private Koru Ankara Hospital is led by the founder of Turkey's National Stem Cell Donor Bank, providing a level of hematologic authority that standard private clinics cannot match.

Patient Consensus: Patients emphasize that while this therapy represents a significant investment, the standard of nursing care during the mandatory 28-day inpatient monitoring period is vital for managing recovery. Many choose Turkey to access specialists with international training from institutions like Harvard and Mayo Clinic.

What is included in a typical CAR T-cell therapy package?

A typical CAR T-cell therapy package in Turkey includes the entire clinical sequence from initial leukapheresis to post-infusion recovery. Core components involve genetically engineering patient T-cells, lymphodepletion chemotherapy, the specialized cellular infusion, and intensive inpatient monitoring for complications like cytokine release syndrome.

  • Medical evaluations: Includes PET/CT scans, biopsies, ECG mapping, and consultations with multi-disciplinary hematology-oncology teams.
  • Clinical manufacturing: Covers T-cell collection via leukapheresis, laboratory genetic modification, and rigorous quality control testing.
  • Hospital stay: Packages typically bundle a 28-day inpatient stay for 24-hour nursing and acute monitoring.
  • Patient logistics: Most Turkish centers provide VIP airport-clinic transfers and dedicated international patient coordinators.

Bookimed Expert Insight: While US CAR T-cell therapy costs $525,000 on average, Turkish packages like those at Medical Park Bahcelievler Hospital offer comprehensive care for $300,000. These specific packages are distinguished by including a full 28-day hospital stay rather than the standard 7–14 days elsewhere. This longer inpatient period is a critical safety buffer, as it ensures immediate access to specialized care during the entire high-risk window for neurotoxicity.

Patient Consensus: Patients emphasize requesting a detailed breakdown of what monitoring specifically includes, as late-stage follow-up or symptom management medications may sometimes be billed separately. Successful outcomes often depend on verifying upfront what happens if cells do not meet manufacturing quality standards.

How long is the post-infusion monitoring period?

Post-infusion monitoring for CAR T-cell therapy in Turkey typically requires 28 days of continuous hospitalization. This intensive observation period ensures immediate medical intervention for specific complications like cytokine release syndrome or neurological toxicities. Specialized hematology units provide around-the-clock nursing care and daily diagnostic screenings during this phase.

  • Hospital stay: Protocols at JCI-accredited centers include a mandatory 28 days of inpatient monitoring.
  • Vital tracking: Medical teams conduct 24-hour nurse monitoring of blood pressure, temperature, and oxygen.
  • Neurological checks: Doctors perform daily symptom logs to detect early signs of immune effector cell-associated neurotoxicity.
  • Diagnostic frequency: Patients undergo frequent blood tests and screenings to manage liver function and platelets.

Bookimed Expert Insight: While global guidelines suggest 14 days, top-tier Turkish centers like Istanbul Florence Nightingale Hospital bundle 28 days of hospitalization into their standard CAR T-cell packages. This extended stay provides a significant safety buffer for managing delayed reactions without incurring extra daily room costs, which can protect your budget from unexpected medical inflation.

Patient Consensus: Many patients find the 2-week mark most critical for monitoring fevers, often requiring a total stay of 18 days if mild complications arise. Experts recommend packing for isolation and verifying that the facility follows European Medicines Agency protocols for cytokine release syndrome.

What types of cancer can be treated with CAR T-cell therapy in Turkey?

CAR T-cell therapy in Turkey primarily treats refractory or relapsed blood cancers, including B-cell Acute Lymphoblastic Leukemia (B-ALL), Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma. Leading JCI-accredited centers in Istanbul and Ankara utilize this genetically modified T-cell infusion for advanced hematologic malignancies.

  • Pediatric leukemia: High success rates for B-cell Acute Lymphoblastic Leukemia in children and adults.
  • Aggressive lymphomas: Effective for Diffuse Large B-cell Lymphoma and advanced Follicular Lymphoma cases.
  • Multiple myeloma: Available for patients resistant to proteasome inhibitors and standard immunomodulatory drugs.
  • Clinical trials: Ongoing research targets solid tumors like brain, lung, and prostate cancers.

Bookimed Expert Insight: While many clinics offer CAR-T, the 28-day mandatory hospital stay is a critical differentiator. Centers like Medical Park Bahcelievler provide full-board hospitalization within their $300,000 packages. This long-term monitoring is essential for managing cytokine release syndrome, a common side effect of this intensive immunotherapy.

Patient Consensus: Patients emphasize that CAR-T is strictly for advanced, relapsed cases. Many survivors recommend confirming specific indications like DLBCL with clinic databases before traveling to ensure eligibility for these high-cost treatments.

What is the success rate of CAR T-cell therapy in Turkey?

CAR T-cell therapy success rates in Turkey range from 58% to 83% for most blood cancers. Specialized university hospitals report efficacy reaching 80% to 90% for pediatric Acute Lymphoblastic Leukemia. Academic trials like ISIKOK-19 for CD19+ tumors demonstrate an overall response rate of 72%.

  • Leukemia outcomes: Pediatric patients show up to 80% efficacy in leading Turkish university centers.
  • Lymphoma response: Patients achieve a 55% overall response rate with 25% reaching complete remission.
  • Clinical trial results: The ISIKOK-19 trial reported complete responses in 66% of leukemia participants.
  • Inpatient monitoring: Success requires 28 days of specialized hospitalization to manage potential side effects.

Bookimed Expert Insight: While success rates are high, the $100,000 price difference between packages at Istanbul Florence Nightingale and Medical Park Bahcelievler often reflects inclusive diagnostics. Lower-priced tiers usually cover the infusion and monitoring, whereas premium packages bundle extensive pre-treatment PET/CT scans and multidisciplinary consultations.

Patient Consensus: Individuals value the direct access to professors trained at institutions like Harvard or Cincinnati. However, some find the standard 28-day isolation period during cell recovery to be emotionally taxing despite the high clinical success.

How are side effects managed?

Managing side effects for CAR T-cell therapy in Turkey involves intensive 28-day hospitalization for continuous monitoring by JCI-accredited hematology teams. Specialists use standardized protocols like tocilizumab infusions for cytokine release syndrome and levetiracetam for neurotoxicity to ensure patient safety during the critical 4-week recovery period.

  • Cytokine management: Surgeons use tocilizumab or siltuximab to resolve grade 2 CRS within 48 hours.
  • Neurological monitoring: Teams provide 24/7 nursing and EEG monitoring to manage ICANS with specific steroids.
  • Infection prophylaxis: Patients receive acyclovir and antifungals pre-lymphodepletion to prevent complications during neutropenia.
  • Long-term support: B-cell aplasia is managed with intravenous immunoglobulin (IVIG) infusions every 3-4 weeks.

Bookimed Expert Insight: While US centers often transition to outpatient care, Turkish clinics like Medical Park Bahcelievler mandate a full 28-day hospital stay. This longer inpatient phase allows JCI-certified teams to catch fever spikes immediately, which is vital since cytokine release syndrome often requires intervention within minutes to maintain high success rates.

Patient Consensus: Patients emphasize the necessity of daily bloodwork and 24/7 nursing support. Many recommend confirming the clinic has immediate ICU access and a steady supply of tocilizumab before starting the 4-week stay.

What is the recovery period post-CAR T-cell infusion?

Recovery after CAR T-cell infusion typically spans 3 to 12 months, beginning with a critical 28-day acute monitoring phase. Patients generally remain hospitalized for 10 to 28 days in JCI-accredited Turkish facilities to manage potential side effects like cytokine release syndrome or neurotoxicity.

  • Hospitalization period: Most Turkish protocols require a 28-day stay for immediate medical surveillance.
  • Acute phase: Days 0–28 focus on monitoring cytokine release syndrome and neurological symptoms.
  • Driving restrictions: Patients must avoid driving for 8 weeks due to delayed seizure risks.
  • Immune reconstitution: Full recovery of the immune system often takes 6 to 12 months.
  • Long-term follow-up: Annual monitoring continues for up to 15 years to track late complications.

Bookimed Expert Insight: While standard protocols suggest a 14-day stay, top-tier Turkish clinics like Istanbul Florence Nightingale or Medical Park Bahcelievler often bundle a full 28-day hospitalization. This longer stay, often supervised by specialists trained at the Mayo Clinic or Harvard, ensures that the most volatile recovery window is managed entirely by clinical experts rather than in a hotel.

Patient Consensus: The first 2 weeks are often the most challenging, characterized by severe flu-like symptoms and high fevers. Most patients report significant energy improvements by month 3, though strict infection precautions remain vital for nearly a year.

What is typically included in a CAR T-cell treatment package?

A CAR T-cell treatment package in Turkey includes T-cell collection via apheresis, genetic engineering in GMP-compliant labs, lymphodepleting chemotherapy, and the cellular infusion. These bundles specifically feature an extended 28-day hospital stay for intensive monitoring of cytokine release syndrome within JCI-accredited hematology-oncology units.

  • Medical screening: Includes PET/CT scans, biopsies, ECG mapping, and consultations with multidisciplinary specialist teams.
  • Cell manufacturing: Covers laboratory genetic engineering and expansion of T-cells in specialized facilities.
  • Inpatient care: Provides 28 days of hospitalization with 24-hour nursing and acute side-effect management.
  • Logistics support: Encompasses VIP airport-to-clinic transfers and dedicated personal coordinators for international patients.

Bookimed Expert Insight: While US CAR T-cell therapy costs average $525,000, Turkish packages offer savings of 64% with a significant clinical advantage. Turkish protocols at centers like Medical Park often include a full 28-day hospital stay, whereas international standards sometimes move to outpatient care after 7–14 days. This extended inpatient period ensures immediate professional intervention for late-onset neurotoxicity without the patient needing to arrange local near-hospital housing.

Patient Consensus: Patients emphasize the importance of choosing packages with all-inclusive diagnostic testing to avoid unexpected billing. Many highlight that having a companion stay during the month-long hospitalization is essential for emotional support during the recovery phase.